Furlan G
Ospedale Civile Maggiore di Verona, Divisione di Chirurgia Toracica e Cardiovascolare, Italia.
Pediatr Med Chir. 1989 May-Jun;11(3):293-9.
In the last two decades improvements in immunosuppression, surgical technique and graft preservation has impressively enhanced transplantation late results. In the present paper we wonder whether this surgical procedure has a role in the treatment of patients with end-stage respiratory disease as cystic fibrosis (CF). We also try to relate on the main clinical, histological development, present status and the real therapeutic value of cardiopulmonary and double-lung transplantation for end-stage CF. We believe lung transplant may well extend the patient life and give a better quality of life to CF patients who would otherwise die, although functional time is presently unknown. Next years challenge ought to be to go critically through clinical results, to focus on existing problems, together with developing appropriate solutions so to allow a better surgical indication of pulmonary transplantation.
在过去二十年中,免疫抑制、手术技术和移植物保存方面的改进显著提高了移植的远期效果。在本文中,我们探讨这种手术方法在治疗终末期呼吸系统疾病如囊性纤维化(CF)患者中是否具有作用。我们还试图阐述心肺移植和双肺移植治疗终末期CF的主要临床情况、组织学发展、现状及实际治疗价值。我们认为肺移植很可能延长患者生命,并为那些否则将会死亡的CF患者提供更好的生活质量,尽管目前功能持续时间尚不清楚。未来几年的挑战应该是严格审视临床结果,关注现存问题,并制定合适的解决方案,以便能更好地进行肺移植的手术指征判断。